Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVD900 on-demand treatment for hereditary angioedema attacks
NL-OMON48423Phase 2Active, not recruiting
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (2 arms), sponsored by KalVista Pharmaceuticals. Primary endpoint: Time to use of conventional attack treatment. Started Jul 2019; status: active, not recruiting.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on NL-OMON48423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48423.